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Abstract
Oxidative skeletal muscles are more resistant than glycolytic muscles to cachexia caused by chronic heart failure and other
chronic diseases. The molecular mechanism for the protection associated with oxidative phenotype remains elusive. We
hypothesized that differences in reactive oxygen species (ROS) and nitric oxide (NO) determine the fiber type susceptibility.
Here, we show that intraperitoneal injection of endotoxin (lipopolysaccharide, LPS) in mice resulted in higher level of ROS
and greater expression of muscle-specific E3 ubiqitin ligases, muscle atrophy F-box (MAFbx)/atrogin-1 and muscle RING
finger-1 (MuRF1), in glycolytic white vastus lateralis muscle than in oxidative soleus muscle. By contrast, NO production,
inducible NO synthase (iNos) and antioxidant gene expression were greatly enhanced in oxidative, but not in glycolytic
muscles, suggesting that NO mediates protection against muscle wasting. NO donors enhanced iNos and antioxidant gene
expression and blocked cytokine/endotoxin-induced MAFbx/atrogin-1 expression in cultured myoblasts and in skeletal
muscle in vivo. Our studies reveal a novel protective mechanism in oxidative myofibers mediated by enhanced iNos and
antioxidant gene expression and suggest a significant value of enhanced NO signaling as a new therapeutic strategy for
cachexia.
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Introduction
Chronic diseases are often associated with and exacerbated by
loss of lean body mass known as cachexia mainly due to skeletal
muscle wasting. Recent research efforts have led to the current
understanding of the molecular and signaling mechanisms
responsible for skeletal muscle atrophy under various pathological
conditions [1–7]. In particular, enhanced expression of muscle-
specific E3 ligases, MAFbx/atrogin-1 and MuRF1, with function in
protein ubiquitination have been shown to mediate proteosome-
dependent protein degradation in muscle wasting. Therefore,
expression of these genes is now served as an early marker of
skeletal muscle atrophy. Skeletal muscles of different fiber type
composition have different contractile and metabolic properties.
Oxidative muscles (predominantly type I and/or IIa fibers) are
generally rich, while glycolytic muscles (predominantly type IId/x
and/or IIb fibers) are poor, in mitochondria and capillaries.
Interestingly, oxidative muscles are more resistant to atrophy than
glycolytic muscles [8–13]; however, much remains unknown
regarding the molecular mechanism(s) for the fiber type-specific
muscle wasting. The ‘‘built-in’’ protection in oxidative myofibers
provides an excellent experimental model to decipher the skeletal
muscle wasting process and search for new drug target(s) to treat
this detrimental symptom that affects the morbidity and mortality
of many chronic diseases.
ROS are well recognized to have primarily deleterious effects in
mammalian cells. High level, sustained increase in ROS leads to
oxidative cellular injury that plays ‘‘cause-effect’’ roles in the
pathogenesis of chronic diseases and syndromes including
cachexia. The deleterious role of ROS in muscle wasting has
been shown in previous studies. Firstly, increased production of
ROS [14–17] and reduced antioxidant gene expression [18] are
associated with muscle catabolism. Secondly, exogenous ROS
activate proteosome-dependent protein degradation [6]. Lastly,
antioxidant treatment attenuates skeletal muscle atrophy [19,20].
However, little is known about the fiber type differences of
oxidative stress in skeletal muscle in cachexia.
The functional role of nitric oxide (NO) and related oxides of
nitrogen (reactive nitrogen species, RNS) in skeletal muscle
wasting is controversial and far less well understood except that
it is well known that NO synthase (NOS) expression is often
increased in muscle wasting disorders [11,21–25]. On the one
hand, NO and RNS have been shown to acutely inhibit
mitochondrial respiration and muscle contractile function
[21,25–27]; thus a scavenger of ROS-RNS [23] or NOS inhibitor
[25] prevents muscle dysfunction. On the other hand, iNOS
expression has been shown to increase dramatically in disease-
resistant oxidative muscles following pathological challenges, and
iNOS inhibition increases disease susceptibility [11]. Furthermore,
chronic inhibition of NOS resulted in muscle dysfunction and
atrophy [28]. In light of these apparently conflicting findings, the
functional role of NO and its derivatives in skeletal muscle wasting
remain to be determined. In particular, there has not been an
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2086attempt to define the functional relationship between ROS and
NO in skeletal muscle under the catabolic condition.
We have recently obtained comprehensive physiological,
morphological, biochemical and gene expression evidence in a
mouse model of chronic heart failure to indicate that oxidative
myofibers are more resistant than glycolytic myofibers to chronic
heart failure [12]. Consistently, there are significant differences
between these myofibers in their atrophic response to cachetic
stimuli, such as LPS and TNF-a. To improve our understanding
of the mechanism(s) underlying the protection associated with
oxidative phenotype, we designed this study to focus on fiber type-
specific differences in ROS and NO and to determine if NO plays
a functional role of muscle atrophic process related to cachexia.
We obtained evidence that oxidative muscles had greater
production of NO and expression of antioxidant genes, and
endure lower oxidative burden than glycolytic muscles in response
to cachectic stimuli. We then tested the hypothesis that up-
regulation of antioxidant genes were dependent on NO, and
thereby provided the protection from cachectic stimuli. This
hypothesis was confirmed both in cultured muscle cells and in
intact skeletal muscle in vivo. Results from this study provide
potential mechanistic insights into the relatively greater resistance
to cachexia associated with oxidative phenotype in skeletal muscle.
Results
Endotoxin induces less ROS production and muscle-
specific E3 ligase expression in mouse oxidative soleus
muscle than in glycolytic white vastus lateralis muscle
Oxidative myofibers are resistant to cachectic stimuli induced by
chronic heart failure and inflammatory cytokines [12]. One possible
explanation is that systemic inflammation induces less oxidative
stress in oxidative than in glycolytic myofibers. To test this
hypothesis, we injected mice with endotoxin and measured protein
carbonylation as an index of oxidative stress. LPS injection
(12 hours) did not result significant changes in carbonylated proteins
in soleus muscles, but resulted in a significant (,50%) increase in
white vastus lateralis muscles (Fig. 1A and 1B). LPS induced greater
expression of muscle-specific E3 ligase MAFbx/atrogin-1 [1,3,4] in
white vastus lateralis muscles than in soleus muscles (Fig. 1C and
1D). LPS also significantly increased MuRF1 expression in vastus
lateralis muscles, but not in soleus muscles (Fig. 1C and 1E). These
findings are completely consistent with our previous findings [12].
Thus, endotoxin challenge results insignificantly lessoxidativestress,
hence less activation of the proteosome-dependant protein degra-
dation, in oxidative than in glycolytic muscles. We have also
observed similar changes in a mouse model of sepsis induced by S.
aureas infection (unpublished results). Therefore, the fiber type-
specific muscle atrophic response appears to be relevant to various
cachectic conditions that can be recapitulated by endotoxin
injection.
Endotoxin induces greater NO production and iNOS
expression in mouse oxidative soleus muscle than in
glycolytic white vastus lateralis muscle
To understand the possible functional role of NO-dependent
signaling/gene regulation in fiber type specificity of muscle wasting,
we assessed NO production in both soleus and white vastus lateralis
muscles by measuring the stable NO product, nitrite. Nitrite
concentration was not significantly different between these two
muscles under basal conditions. However, LPS injection led to
,100%increase innitrite concentration insoleus muscles,but notin
white vastus lateralis muscles (Fig. 2A). The increase in nitrite in
soleus muscle was associated with an enhanced iNOS expression
(Fig. 2B, 2C and 2F) with majority of protein confined to the
periphery of oxidative myofibers. In contrast, neuronal NO synthase
(nNos) expression was reduced in both soleus and white vastus
lateralis muscles (Fig. 2D), whereas endothelial NO synthase (eNos)
expression was low in white vastus lateralis muscles under basal
conditions and was induced to a level comparable to that in the
soleus muscles (Fig. 2E) following LPS injection. These findings
suggest that oxidative myofibers have great inducibility in NO
production, probably through induced expression of iNOS.
Endotoxin induces greater antioxidant gene expression
in oxidative soleus muscle than in glycolytic white vastus
lateralis muscle
Our finding of less oxidative stress in soleus muscles than white
vastus lateralis muscles following endotoxin challenge prompted us
to determine if enhanced antioxidant gene expression contributes to
the protection of oxidative myofibers. We performed semi-
quantitative RT-PCR analysis for mRNA of the antioxidant genes:
superoxide dismutases (Sod1, Sod2 and Sod3) and catalase (Cat). LPS
injection resulted in significantly increased expression for all four
antioxidant genes in soleus muscles with no or less increases in white
vastus lateralis muscles (Fig. 3A–E). We have, therefore, obtained
evidence for differentially enhanced antioxidant gene expression in
oxidative vs. glycolytic myofibers that are likely intrinsic to the
muscles.
NO donor blocks TNF-a-induced muscle-specific E3 ligase
expression and enhances iNOS and antioxidant gene
expression in cultured muscle cells
Our findings that there are greater increases in NO production
and antioxidant gene expression in oxidative than glycolytic muscles
inresponsetocachecticstimulisuggestafunctionallinkbetweenNO
production and the antioxidant defense system. To test this
hypothesis, we cultured mouse C2C12 myoblasts with TNF-a in
the presence and absence of NO donor, diethylenetriamine NO
(DETA-NO). DETA-NO resulted in a moderate, but significant,
reduction in the basal level expression MAFbx/atrogin-1 mRNA and
completely blocked the induction of MAFbx/atrogin-1 induced by
TNF-a (Fig. 4A and 4B). DETA-NO enhanced TNF-a-induced iNos
expression significantly (Fig. 4C and 4D). These findings indicate
that NO is sufficient to reduce cytokine-induced activation of the
proteosome-dependent catabolic pathway, which appears to be
mediated by iNOS. To determine if NO induces antioxidant gene
expression, we performed semi-quantitative RT-PCR analysis for
Sod1, Sod2, Sod3 and Cat. DETA-NO increased the basal level and
TNF-a-induced Sod3 and Cat expression, whereas Sod1 and Sod2
werenotresponsive(Fig.4E–4I),suggestingthatSod3 andCatplayan
important role in mitigating oxidative stress induced by cytokines in
myocytes. To further confirm that these findings are due to NO-
dependent transcriptional activation of the antioxidant genes, we
transfected C2C12 myoblasts with the antioxidant response element
(ARE) TATA-Inr luciferase reporter gene, pARE-Luc [29], and
treated the myoblasts with or without DETA-NO for 24 hours [30].
The reporter gene expression was significantly stimulated by NO
donor, suggesting that NO stimulates antioxidant genes through the
cis-acting ARE DNA sequences.
S-nitrosoglutathione (GSNO) blocks endotoxin-induced
muscle-specific E3 ligase expression and enhances iNOS
and antioxidant gene expression in skeletal muscle in vivo
The findings in cultured muscle cells motivated an in vivo study to
confirm the functional role of NO in intact skeletal muscle. We
Skeletal Muscle Wasting
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i.p.; 6 hours before and immediately before LPS injection) and
performed semi-quantitative RT-PCR analysis in plantaris muscles
(a muscle with a mixture of both oxidative type IIa and glycolytic
type IId/x and IIb fibers). GSNO effectively blocked MAFbx/atrogin-
1 mRNAexpression induced by LPS (Fig. 5A and5B) andpromoted
iNosmRNAexpression bothwith and without LPS injection (Fig. 5C
and 5D). Therefore,NOprotectsmyofibersfrom endotoxin-induced
oxidative stress and prevent activation of the proteosome-dependent
catabolic pathway, possibly through induced expression of iNOS.
RT-PCR analysis for Sod1, Sod2, Sod3 and Cat in plantaris muscles
showed that GSNO resulted in increases in Sod3 and Cat,b u tn o t
Sod1 and Sod2, expression with and without LPS injection (Fig. 5E–
5I). These findings were entirely consistent with the findings in
cultured myoblasts,suggesting theimportanceof SOD3 andCAT in
NO-mediated protection against cachetic stimuli.
Discussion
The mechanisms underlying the protection of oxidative
myofibers against cachexia have been unclear. The major findings
of this study are: 1) Protein oxidation and degradative protein
(muscle-specific E3 ubiquitin ligase) expression were lower in
oxidative than in glycolytic muscles in response to cachectic
stimuli; 2) iNOS expression, NO production and antioxidant gene
expression were higher in oxidative muscles than in glycolytic
muscles; and 3) NO donors enhanced iNOS and antioxidant gene
expression and attenuated atrophic muscle responses both in vitro
and in vivo. These findings together strongly suggest that NO-
dependent up-regulation of the antioxidant genes, at least partly
mediated by iNOS, protects oxidative myofibers against cachectic
stimuli. The studies not only provide potential mechanistic insights
into the functional protection in oxidative muscle fibers, but also
Figure 1. Endotoxin induces less oxidative stress and proteosome-dependent protein degradation in mouse oxidative than in
glycolytic muscles. Whole muscle homogenates and total RNA from oxidative soleus muscles (SO) and glycolytic white vastus lateralis muscles
(WV) 12 hours after intraperitoneal (i.p.) injection of LPS (1 mg/kg body weight) were assayed for the carbonyl groups by immunoblot analysis (A and
B) and for MAFbox/atrogin-1 and MuRF1 mRNA expression by semi-quantitative RT-PCR (C, D and E). A) Immunoblots show total protein carbonylation
(top panel) after LPS or saline injection (Con) with a-tubulin (bottom panel) as loading reference. Each lane was loaded with 20 mg of proteins, and
data were shown in triplicates; B) Quantification and comparison of protein carbonylation (n=12; ** P,0.01); C) Gel images show semi-quantitative
RT-PCR analysis for MAFbx/atrogin-1 and MuRF1 mRNA expression with 18S ribosomal RNA as control; and D) and E) Quantification and comparison of
MAFbx/atrogin-1 and MuRF1 mRNA expression. The SO muscles from saline injected mice were set as reference (n=6; ** and *** P,0.01 and 0.001,
respectively).
doi:10.1371/journal.pone.0002086.g001
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treatment of muscle wasting.
The fiber type-specific muscle wasting could be due to an
intrinsic difference(s) in the oxidant/antioxidant system. We have
recently shown that oxidative myofibers are protected from
cachectic stimuli, such as LPS and TNF-a [12]. The finding in
this study that endotoxin resulted in significantly less protein
oxidation in oxidative muscle than in glycolytic muscle (Fig. 1A
and 1B) is consistent with the notion that a more robust basal and/
or inducible antioxidant system in oxidative myofibers prevents
ROS from accumulating to a high level causing cellular damage.
In fact, it has been shown that oxidative muscles have more robust
expression and activity of antioxidant enzymes than glycolytic
muscles [31,32], and there is less mitochondrial superoxide
production in oxidative myofibers than glycolytic myofibers [33].
Our findings of enhanced antioxidant gene expression in oxidative
muscles (Fig. 3A–3E) suggest that an inducible antioxidant system
provides additional protection against muscle catabolism. Eluci-
dation of the mechanism responsible for such an inducible defense
system will likely lead to the discovery of new drug target(s) for
cachexia.
We also found that oxidative muscles produce more NO than
glycolytic muscle and exhibit attenuated atrophic responses
following endotoxin challenge (Fig. 2A), raising the possibility of
a cause-effect relationship between NO and muscle protection.
Paradoxically, it has been shown that NO and RNS inhibit
mitochondrial respiration and muscle contractile function [21,25–
27], which could be prevented by ROS-RNS scavengers [23] or
NOS inhibitors [25]. The interpretation was that iNOS mediated
NO production was detrimental to muscle wasting. These previous
findings were obtained in ex vivo experiments focusing on the acute
effect of NO on muscle metabolic and contractile functions.
Therefore, the mechanism(s) by which NO may protect against
long-term muscle injury is currently not known. Our fiber type-
specific analysis provides exciting new insight, suggesting induced
NO production may play a protection against cachectic stimuli,
rather than mediate muscle wasting.
NO production in skeletal muscle could involve nNOS (NOS1),
iNOS (NOS2) and/or eNOS (NOS3) as they have been detected
in skeletal muscles. A recent study showed that LPS injection
resulted in increased NO production and changes in redox state in
skeletal muscle, which were absent in iNos
2/2 mice [23],
Figure 2. Endotoxin induces greater iNOS expression and NO production in mouse oxidative than in glycolytic muscles. Whole
muscle homogenates, total RNA and muscle sections from SO and WV after LPS or saline injection were assayed for nitrite (A), iNos, nNos and eNos
mRNA expression by semi-quantitative RT-PCR (B,C, D and E), and iNOS protein expression by immunofluorescence (F). A) Quantification and
comparison of nitrite concentration (n=5–6; ** P,0.01); B) Gel images show levels of iNos, nNos and eNos mRNA expression with 18S ribosomal RNA
as control; C), D) and E) Quantification and comparison of iNos, nNos and eNos mRNA expression. The SO muscles from saline injected mice were set
as reference (n=9; ** and *** P,0.01 and 0.001, respectively); and F) Immunofluorescence staining for iNOS protein after LPS or saline (Con)
injections (12 hours), showing higher level of basal and induced expression of iNOS in SO vs. WV muscles.
doi:10.1371/journal.pone.0002086.g002
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observed that induced iNOS expression was associated with
increased NO production in oxidative muscle that was protected
from endotoxin challenge (Fig. 2A, 2B, 2C and 2F). In contrast,
endotoxin resulted in decreased nNos expression in both oxidative
and glycolytic muscles (Fig. 2B and 2D). nNOS protein is
specifically expressed in glycolytic myofibers as part of dystrophin
glycoprotein complex [34] that maintains skeletal muscle contrac-
tile function [35,36]; reduced nNos expression here is consistent
with a general sarcolemmal injury [36]. On the other hand,
induced eNos expression in glycolytic myofibers (Fig. 2B and 2E)
does not reconcile with the protection in oxidative myofibers.
Taken together, cachexia-induced NO production in skeletal
muscle appears to be mediated through enhanced iNOS
expression. The apparent feed-forward regulation of NO produc-
tion may prove to be critical in amplifying the signals necessary for
the protection associated with oxidative phenotype.
Paradoxically, melatonin, a powerful scavenger of both ROS and
RNS, abolished the increases in NO production and GSSG/GSH
ratio in isolated mitochondria from skeletal muscles [23] and heart
[37] in mice challenged with endotoxin; these increases were absent
in iNos
2/2 mice. Our confined staining of oxidative myofibers of
iNOS to the periphery is most consistent with mitochondrial
localization of iNOS protein, which is in agreement with a recent
finding [23]. The previous findings that cachetic responses were
absent in iNos
2/2 mice were interpreted as evidence that iNOS was
responsible for mitochondrial dysfunction and oxidative stress in
muscles wasting. However, precaution should be taken regarding
these findings with overall inhibition of iNOS since whole body
genetic disruption of the iNos gene and application of iNOS inhibitor
leads to loss of iNOS function not only inskeletal muscles, but also in
macrophages,whichiscriticalfortheinductionofsepsis[38].Onthe
other hand, a powerful protective function of iNOS in skeletal
muscle are suggested in previous studies using a rat model of
myasthenia gravis [11] caused by autoantibodies binding to and
inhibiting the nicotinic acetylcholine receptors at the neuromuscular
junctions. iNOS inhibitor converted disease-resistant soleus muscle
toadisease-susceptiblephenotype[11].Inthisstudy,bothinvitroand
in vivo findings provide strong evidence support the protective
function of NO inskeletal muscleincachexia. Nevertheless, a formal
Figure 3. Endotoxin induces greater antioxidant gene expression in mouse oxidative than in glycolytic muscles. Total RNA from SO
and WV after LPS or saline (Con) injection were assayed for antioxidant gene expression by semi-quantitative RT-PCR. A) Gel images show levels of
Sod1, Sod2, Sod3 and Cat mRNA expression with 18S ribosomal RNA as control; and B), C), D) and E) Quantification and comparison of Sod1, Sod2,
Sod3 and Cat mRNA, respectively (n=9; *, ** and *** P,0.05, 0.01 and 0.001, respectively).
doi:10.1371/journal.pone.0002086.g003
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generation of an animal model of skeletal muscle-specific knockout
of the iNos gene.
We observed significant enhanced antioxidant genes in
oxidative soleus muscles, but not in glycolytic white vastus lateralis
muscles (Fig. 3A–3E), a first demonstration of fiber type-specific
induction of antioxidant genes in a whole animal model of muscle
wasting. We then addressed the question whether enhanced NO
production/signaling renders protection against cachetic stimuli
induced by endotoxin/cytokine. Both in vitro and in vivo findings
suggest that NO reduces atrophic responses and enhances
antioxidant gene expression in skeletal muscles (Fig. 4 and 5).
To our knowledge, this is the first demonstration of simultaneous,
fiber type-specific induction of Sod3 and Cat. Based on these
findings, we now conclude that oxidative myofibers possess an
intact NO-dependent signaling and transcription system protect-
ing the myofibers from oxidative stress by enhancing the
antioxidant system. The finding of enhanced reporter gene activity
Figure 4. NO enhances iNos and antioxidant gene expression, and blocks TNF-a-induced MAFbx/atrogin-1 mRNA expression in
cultured myoblasts. Total RNA from cultured C2C12 myoblasts following treatment with NO donor, DETA-NO (0.2 mM), for 24 hours in the
presence or absence of TNF-a (10 ng/ml) were assayed for MAFbx/atrogin-1, iNos and antioxidant gene expression by semi-quantitative RT-PCR and
total protein lysates from transfected C2C12 myoblasts were harvested and assayed for luciferase activities. A) Gel images show levels of MAFbx/
atrogin-1 mRNA expression (in triplicates) with 18S ribosomal RNA as control; B) Quantification and comparison of MAFbx/atrogin-1 mRNA (n=11; **
and *** P,0.01 and 0.001, respectively); C) Gel images show levels of iNos mRNA expression with 18S ribosomal RNA as control; D) Quantification and
comparison of iNos mRNA (n=6; ** P,0.01); E) Gel images show levels of Sod1, Sod2, Sod3 and Cat mRNA expression with 18S ribosomal RNA as
control; F), G), H) and I) Quantification and comparison of Sod1, Sod2, Sod3 and Cat mRNA, respectively (n=6; * and ** P,0.05 and 0.01, respectively);
and J) pARE-Luc reporter gene activity in C2C12 myoblasts treated with or without DETA-NO for 24 hours (n=6; * P,0.05).
doi:10.1371/journal.pone.0002086.g004
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(Fig. 4J) further supports this conclusion and provides more direct
evidence of transcriptional control. Further research should focus
on the link between the NO signal and the transcriptional factors
in skeletal muscle that is responsible for the inducible defense
system.
It is worth noticing that NO donor was sufficient both in vitro
and in vivo to induce iNOS expression (Fig. 4C and 4D and
Figure 5. GSNO enhances iNos and antioxidant gene expression, and blocks LPS-induced MAFbx/atrogin-1 mRNA expression in
mouse plantaris muscles. Total RNA following NO donor GSNO injections (1 mg/kg, i.p. twice) in mice with LPS (1 mg/kg) or saline injection (Con)
were assayed for MAFbx/atrogin-1, iNos and antioxidant enzyme mRNA expression by semi-quantitative RT-PCR. A) Gel images show levels of MAFbx/
atrogin-1 mRNA expression (in triplicates) with 18S ribosomal RNA as control; B) Quantification and comparison of MAFbx/atrogin-1 mRNA (n=11; **
and ***P,0.01 and 0.001, respectively); C) Gel images show levels of iNos mRNA expression with 18S ribosomal RNA as control; D) Quantification and
comparison of iNos mRNA (n=6; ** and *** P,0.01 and 0.001, respectively); E) Gel images show levels of Sod1, Sod2, Sod3 and Cat mRNA expression
with 18S ribosomal RNA as control; and F), G), H) and I) Quantification and comparison of Sod1, Sod2, Sod3 and Cat mRNA, respectively (n=6; * and
** P,0.05, and 0.01, respectively).
doi:10.1371/journal.pone.0002086.g005
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skeletal muscles have intact machineries to induce iNOS
expression; the difference may be that oxidative muscle, but not
glycolytic muscle, has the ability to trigger the initial increase in
NO production. Future experiments should focus on elucidating
the mechanism underlying this important regulatory event.
Accumulating evidence supports the view that NO and RNS play
protective functions in various tissues/organs and disease models
[39–41]. Perhaps, the most relevant findings are in the heart [42,43]
through an iNOS-dependent mechanism [44] as cardiac muscle has
metabolic and contractile functions that more closely resemble
oxidative skeletal muscles. More recently, a calcineurin/NFAT
(nuclear factor of activated T-cells) signaling cascade has been
implicated in cardiomyocyte protection through the transcriptional
control of the iNos gene [45]. Ours is the first report that NO and
RNS play a protectiveroleagainstcacheticstimuliinskeletalmuscle.
We believe that NO elicits signaling events leading to the
transcriptional activation of the antioxidant genes though the exact
signaling and molecular mechanisms responsible for the up-
regulation of the antioxidant genes remain to be elucidated.
In summary, findings from this study are consistent with a
hypothesis as following. Cachexia leads to increased oxidative
stress and consequently activation of protein degradation pathways
in glycolytic myofibers. Enhanced iNOS expression and NO
production lead to enhanced antioxidant gene expression in
oxidative myofibers, providing protection against oxidative stress
(Fig. 6). These findings suggest a therapeutic value of enhancing
NO signaling in skeletal muscle for cachexia. Future investigations
should ascertain the functional role of enhanced NO signaling in
protection against various types of muscle atrophy and elucidate
the molecular mechanism(s) responsible for the fiber type-specific
expression of iNos and antioxidant genes. It should be noted that
skeletal muscle wasting during cachexia could be affected by
protein synthesis, protein degradation, autophagy and other
processes. The finding of linking NO-dependent inducible
antioxidant system to reduced atrogene expression may represent
one of the mechanisms of endogenous defense systems in skeletal
muscle under the condition of cachectic challenges.
Materials and Methods
Experimental animals
MaleC57BL/6mice(8–9weeksold)fromtheJacksonLaboratory
(Bar Harbor, ME) were maintained in light- (12:12 h light-dark
cycle) and temperature-controlled quarter (21uC) provided with
water and chow (Purina, Richmond, IN) ad libitum.T h e yw e r e
intraperitoneally injected (i.p. 1 mg/kg) with E. coli LPS (Sigma, St.
Louis, MO) or normal saline 12 hours before being sacrificed by
isoflurane-induced anesthesia and cervical dislocation. LPS injection
did not result in morbidity or mortality. Soleus and white vastus
lateralis muscles were harvested. To determine the role of NOdonor
in vivo, GSNO (Sigma, St. Louis, MO) were injected (i.p. 1 mg/kg)
twice (6 hours prior to and at the time of LPS or normal saline
injection). Plantaris muscles were harvested 12 hours later. All
animalprotocolswereapproved bytheDuke UniversityInstitutional
Animal Care and Use Committee.
Protein carbonylation assay
To determine the level of oxidative stress in skeletal muscle,
carbonyl levels of proteins were determined in whole muscle
lysates by using the OxyBlot
TM Protein Oxidation Detection Kit
(Serologicals Corporation, Norcross, GA). Briefly, harvested
skeletal muscles were placed in 5-ml Falcon tubes each containing
1 ml of ice-cold Protein Lysis Buffer (Cell Signaling Technology,
Danvers, MA) supplemented with 50 mM dithiothreitol (DDT)
and 1 mM phenylmethylsulphonyl fluoride (PMSF) and homog-
enized with an Ultra Turrax T25 Polytron
TM homogenizer. The
homogenates were centrifuged at 16,000 6 g for 5 min at 4uC,
and the supernatants were then transferred to 10K NMMWL-
0.5 ml Ultrafree Filter Unit (Millipore, Bedford, MA) and
centrifuged at 16,000 6 ga t4 uC (about 30 min) to concentrate
to a volume of about 60 ml. Protein concentration was then
determined by using the RC DC protein assay (BioRad, Hercules,
CA). Protein carbonylation was then determined in the whole
muscle lysate (20 mg protein) by an immunblot-based assay
according to the instructions from the manufacturer. The
intensities of all the bands in each of the lanes were quantified
by using Scion Image (Scion Corporation, Frederick, Maryland)
and normalized by a-tubulin.
Nitrite assay
Nitrite was assessed using the Griess Reagent System (Promega,
Madison, WI). In brief, harvested skeletal muscles were homog-
enized immediately in ice-cold Protein Lysis Buffer (Cell Signaling
Technology, Danvers, MA) containing 1 mM PMSF in a
Wheaton glass-on-glass homogenizer on ice, and the homogenate
was centrifuged at 16,000 6 g for 5 min at 4uC. The protein
concentration of the supernatants was determined as described
above. The nitrite assay was started by adding the sample (360 mg
proteins in 50 ml) to 50 ml sulfanilamide solutions in 96-well plates
in duplicate. After incubation at room temperature for 10 min,
50 ml of the N-1-napthylethylenediamine dihydrochloride (NED)
solution was added, and the reaction was continued for another
10 min. Absorbance at 550 nm was then measured, and nitrite
concentration was calculated after normalization by total protein.
Cell culture
C2C12 mouse myoblasts were grown and maintained as sub-
confluent monolayer in high-glucose Dulbecco modified Eagle
Figure 6. Schematic presentation of a novel framework for
oxidative phenotype-associated protection against muscle
wasting. Cachectic factors increase ROS in glycolytic myofibers;
oxidative stress in turn results in up-regulation of atrophic genes
(atrogenes), enhances protein degradation and muscle atrophy. ROS are
reduced in oxidative myofibers due to expression of iNOS and NO-
dependent up-regulation of the antioxidant genes, leading to less
atrogene expression and protein degradation. Thick and thin arrows
represent great and little increase/stimulation, respectively.
doi:10.1371/journal.pone.0002086.g006
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with 20% fetal bovine serum (FBS, Gibco BRL, Grand Island,
NY). To examine the effect of NO donor and iNOS inhibitor,
C2C12 cells seeded in 35 mm-wells at 1 6 10
5 and allowed to
adhere for at least 12 hour prior to stimulation by TNF-a (R&D
Systems, Minneapolis, MN) at 10 ng/ml with/without DETA-NO
(Sigma, St. Louis, MO). The cells were harvested 20 hours later,
and total RNA samples were isolated for RT-PCR analysis by
using Trizol (Invitrogen, Carlsbad, CA). For transfection of pARE-
Luc, C2C12 myoblasts were transfected with 0.5 mg with
Lipofectamine 2000 according the manufacturer’s instructions.
After overnight transfection, the transfected cells were treated
with/without DETA-NO (10 ng/ml) for 24 hours. Luciferase
activity was assayed and is expressed as relative activity (fold
change) in comparison to the value of transfected cells without
DETA-NO. The transfection was done twice with triplicate
samples for each condition.
Semi-quantitative RT-PCR
This analysis was performed as described [12] to measure
MAFbx/atrogin-1, MuRF1, iNos, superoxide dismutases (Sod-1, Sod-
2, Sod-3) and catalase (Cat) mRNA expression in skeletal muscles
and in cultured C2C12 myoblasts. PCR primer pairs were
designed using Primer3 search engine at www-genome.wi.mit.edu.
The oligonuleotide primer pairs used in this study corresponded to
the following nucleotides: MAFbx/atrogin-1: 1917–1936 and 2415–
2396 (NM_026346); MuRF1: 50–69 and 452–433 (AF294790);
iNos: 1815–1834 and 2301–2282 (MMU43428); eNOS: 1515–1534
and 2002–1983 (NM_008713); nNOS: 1261–1272 and 1735–1716
(NM_008712); Sod1: 168–187 and 583–564 (NM_011434); Sod2:
1218–1237 and 1647–1628 (BC066063); Sod3: 1547–1566 and
2019–2000 (NM_011435); and Cat: 237–256 and 645–626
(MMU43428). Results were normalized by 18S rRNA and
presented as fold change to soleus muscle in mice injected with
normal saline.
Statistics
Data are presented as mean6standard error. For comparisons
involving two factors, two-way ANOVA was performed followed
by the Newman-Kuels test. For comparisons between two groups,
the Student t-test was performed. P,0.05 was accepted as
statistically significant for all the experiments in this study.
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